Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 27 04:00PM ET
27.02
Dollar change
+0.76
Percentage change
2.89
%
IndexRUT P/E- EPS (ttm)-5.42 Insider Own2.30% Shs Outstand96.11M Perf Week-2.74%
Market Cap2.60B Forward P/E- EPS next Y-5.64 Insider Trans-2.37% Shs Float93.89M Perf Month-12.89%
Income-481.19M PEG- EPS next Q-1.38 Inst Own85.60% Short Float14.38% Perf Quarter-16.45%
Sales36.27M P/S71.60 EPS this Y-2.56% Inst Trans-0.30% Short Ratio8.54 Perf Half Y-16.48%
Book/sh11.29 P/B2.39 EPS next Y-1.39% ROA-34.11% Short Interest13.50M Perf Year-27.27%
Cash/sh9.49 P/C2.85 EPS next 5Y30.00% ROE-42.10% 52W Range22.67 - 47.48 Perf YTD-11.38%
Dividend Est.- P/FCF- EPS past 5Y-22.30% ROI-41.96% 52W High-43.09% Beta1.78
Dividend TTM- Quick Ratio8.67 Sales past 5Y12.09% Gross Margin75.26% 52W Low19.21% ATR (14)1.52
Dividend Ex-Date- Current Ratio8.67 EPS Y/Y TTM12.31% Oper. Margin-1420.51% RSI (14)44.47 Volatility4.12% 5.55%
Employees526 Debt/Eq0.11 Sales Y/Y TTM-30.40% Profit Margin-1326.51% Recom1.54 Target Price69.96
Option/ShortYes / Yes LT Debt/Eq0.09 EPS Q/Q-4.64% Payout- Rel Volume0.75 Prev Close26.26
Sales Surprise-115.04% EPS Surprise-1.49% Sales Q/Q-114.12% EarningsFeb 22 BMO Avg Volume1.58M Price27.02
SMA20-7.21% SMA50-1.91% SMA200-17.35% Trades Volume1,186,440 Change2.89%
Date Action Analyst Rating Change Price Target Change
Feb-23-24Downgrade Goldman Buy → Neutral $136 → $32
Feb-15-24Initiated Wolfe Research Peer Perform
Apr-13-23Initiated Canaccord Genuity Buy $66
Mar-21-23Initiated Bernstein Outperform $54
Mar-14-23Upgrade BMO Capital Markets Market Perform → Outperform $54 → $57
Feb-01-23Initiated Cantor Fitzgerald Overweight $67
Jan-24-23Upgrade Citigroup Sell → Neutral $48 → $39
Jan-19-23Downgrade JMP Securities Mkt Outperform → Mkt Perform
Oct-11-22Initiated Morgan Stanley Overweight $84
Sep-21-22Initiated JP Morgan Overweight $85
Mar-21-24 05:29PM
04:19PM
Mar-19-24 01:06PM
Mar-18-24 07:30AM
Mar-09-24 09:45AM
10:35AM Loading…
Mar-06-24 10:35AM
Mar-01-24 01:43PM
Feb-29-24 05:50AM
Feb-28-24 09:30AM
Feb-27-24 11:55AM
09:35AM
Feb-23-24 12:22PM
11:12AM
09:55AM
Feb-22-24 10:53PM
08:12AM Loading…
08:12AM
07:30AM
Feb-20-24 05:02AM
Feb-17-24 01:59AM
Feb-15-24 10:00AM
07:30AM
06:20AM
Feb-14-24 07:30AM
Feb-13-24 06:05AM
Feb-10-24 05:09PM
Feb-08-24 01:15PM
Feb-07-24 11:50AM
Feb-05-24 05:25AM
Jan-31-24 05:00PM
12:28PM
05:10AM Loading…
Jan-30-24 05:10AM
Jan-29-24 09:35AM
Jan-27-24 01:25PM
08:55AM
Jan-24-24 07:00AM
Jan-22-24 05:41PM
Jan-21-24 08:00AM
Jan-18-24 11:50AM
Jan-13-24 06:05AM
Jan-12-24 08:44AM
Jan-08-24 07:45AM
05:52AM
Jan-05-24 10:04AM
Jan-04-24 04:01PM
12:47PM
Dec-31-23 08:45AM
Dec-27-23 06:41PM
Dec-16-23 05:00AM
Dec-13-23 05:20AM
Dec-12-23 06:00AM
Dec-10-23 11:57AM
Nov-28-23 05:30AM
Nov-24-23 07:00AM
Nov-15-23 11:07AM
Nov-14-23 07:30AM
Nov-10-23 05:38PM
06:30AM
Nov-09-23 04:06PM
03:37PM
08:29AM
07:30AM
Nov-06-23 08:02AM
Nov-02-23 07:00AM
06:45AM
Oct-30-23 03:46PM
10:00AM
Oct-28-23 07:30AM
Oct-26-23 10:02AM
07:30AM
Oct-23-23 09:40AM
08:45AM
Oct-21-23 05:00AM
Oct-19-23 11:46AM
Oct-18-23 04:10PM
07:00AM
Oct-16-23 12:39PM
10:43AM
Oct-14-23 12:20PM
Oct-13-23 08:38AM
Oct-12-23 08:57AM
Oct-10-23 02:00PM
10:07AM
Oct-06-23 04:59AM
Oct-05-23 09:15AM
Oct-04-23 09:27AM
Oct-03-23 10:07AM
07:58AM
07:08AM
07:00AM
Sep-23-23 09:45AM
Sep-10-23 08:15AM
Sep-09-23 03:59PM
Sep-06-23 02:00PM
Sep-05-23 09:52AM
Sep-01-23 10:00AM
Aug-31-23 05:42AM
Aug-30-23 09:37AM
Aug-24-23 10:29AM
Aug-23-23 11:15AM
08:25AM
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BASTA JAMESEVP, General CounselMar 04 '24Sale32.992,29775,77881,571Mar 05 04:10 PM
Clark ElianaEVP, Chief Technical OfficerMar 04 '24Sale32.9960519,95971,470Mar 05 04:10 PM
Sepp-Lorenzino LauraEVP, Chief Scientific OfficerJan 08 '24Sale28.872,27565,68243,927Jan 10 04:15 PM
LEONARD JOHN MPresident and CEOJan 03 '24Sale29.4619,223566,310846,486Jan 05 04:51 PM
Lebwohl DavidEVP, Chief Medical OfficerJan 03 '24Sale29.465,843172,13554,372Jan 05 04:50 PM
Sepp-Lorenzino LauraEVP, Chief Scientific OfficerJan 03 '24Sale29.465,532162,97346,202Jan 05 04:50 PM
Goddard GlennEVP, Chief Financial OfficerJan 03 '24Sale29.465,365158,05340,585Jan 05 04:49 PM
Clark ElianaEVP, Chief Technical OfficerJan 03 '24Sale29.504,608135,95440,845Jan 05 04:44 PM
Hicks DerekEVP, Chief Business OfficerJan 03 '24Sale29.463,877114,21636,987Jan 05 04:46 PM
BASTA JAMESEVP, General CounselJan 03 '24Sale29.463,805112,09551,474Jan 05 04:45 PM
Bhanji MunaDirectorOct 31 '23Sale23.902656,33411,996Nov 02 04:42 PM
Bhanji MunaDirectorJul 31 '23Sale42.3326511,21712,261Aug 02 05:19 PM
Bhanji MunaDirectorJul 06 '23Sale39.301,86773,37312,526Jul 10 05:21 PM
Clark ElianaEVP, Chief Technical OfficerJul 03 '23Sale40.5136014,58445,146Jul 06 03:34 PM
Clark ElianaEVP, Chief Technical OfficerJun 20 '23Option Exercise12.275,00061,35050,146Jun 22 05:52 PM
Clark ElianaEVP, Chief Technical OfficerJun 20 '23Sale45.005,000225,00045,146Jun 22 05:52 PM